biote Corp (BTMD)vsEli Lilly and Company (LLY)
BTMD
biote Corp
$1.22
-0.81%
HEALTHCARE · Cap: $41.70M
LLY
Eli Lilly and Company
$1,183.46
+0.13%
HEALTHCARE · Cap: $1.03T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 43307% more annual revenue ($79.67B vs $183.53M). LLY leads profitability with a 33.5% profit margin vs 3.2%. BTMD trades at a lower P/E of 8.8x. LLY earns a higher WallStSmart Score of 76/100 (B+).
BTMD
Avoid33
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+47.0%
Fair Value
$4.00
Current Price
$1.22
$2.78 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
3.2% margin — thin
Revenue declined 9.5%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : BTMD
The strongest argument for BTMD centers on P/E Ratio, Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : BTMD
The primary concerns for BTMD are Market Cap, Return on Equity, Profit Margin. Thin 3.2% margins leave little buffer for downturns.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
BTMD profiles as a value stock while LLY is a growth play — different risk/reward profiles.
BTMD carries more volatility with a beta of 1.61 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 33/100), backed by strong 33.5% margins and 47.7% revenue growth. BTMD offers better value entry with a 47.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
biote Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
biote corp. The company is headquartered in Irvine, Texas.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?